• FDA expands approval of Vonvendi for von Willebrand disease

    11 monthes ago - By Healio

    The FDA expanded the approval of Vonvendi for the treatment of bleeding in adults with von Willebrand disease to include surgical settings, according to the agent's manufacturer.
    Vonvendi (von Willebrand factor , Shire) - approved by the FDA in 2015 - is the only recombinant treatment for adults with von Willebrand disease, the most common inherited bleeding disorder. In addition to this new indication for the perioperative management of bleeding in adults, Vonvendi is indicated for on-demand treatment and control of bleeding episodes.
    “The expanded approval
    Read more ...